Language Selection

Get healthy now with MedBeds!
Click here to book your session

Protect your whole family with Orgo-Life® Quantum MedBed Energy Technology® devices.

Advertising by Adpathway

         

 Advertising by Adpathway

Insulin Resistance in Early Perimenopause: A Practical Assessment and Treatment Framework

2 hours ago 8

PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY

Orgo-Life the new way to the future

  Advertising by Adpathway

Patients in their early forties often arrive with a cluster of complaints that resist a tidy diagnosis: mid-afternoon fatigue, new central weight gain, sleep that fragments at 3 a.m., and cycles that are still regular enough to look reassuring on paper. The temptation is to treat each symptom on its own. The more useful question is whether insulin signalling has already begun to drift.1

Longitudinal cohort data suggest that the metabolic phase of the menopause transition precedes the endocrine phase by several years. That gap is the clinical opportunity, and it is routinely missed because standard panels stop at fasting glucose and A1c — both of which stay in range long after compensatory hyperinsulinemia begins.2

 

Why standard screening misses the window

Fasting glucose is a lagging indicator. By the time it rises, beta-cell compensation has already been running for years. In practice this means a patient can present with textbook insulin resistance physiology and a completely unremarkable metabolic panel.

 

What to add to the panel

  • Fasting insulin, with HOMA-IR calculated rather than eyeballed
  • Triglyceride-to-HDL ratio as an inexpensive surrogate
  • Waist-to-height ratio, measured at every visit
  • Optional: 2-hour insulin during a 75 g challenge for ambiguous cases

The metabolic phase of the transition precedes the endocrine phase — which is precisely why the standard panel reassures everyone for years longer than it should.— Kareem Kandil, ND

A staged assessment framework

Staging keeps the workup proportionate. Stage one is inexpensive and universal; stage two is reserved for patients whose surrogates are already abnormal.

Stage Tests Act if
1 — Screen Fasting insulin, glucose, lipids, WHtR HOMA-IR > 1.9 or WHtR > 0.50
2 — Characterize 2-h OGTT with insulin, hs-CRP, ALT 2-h insulin > 60 µIU/mL
3 — Monitor Repeat stage 1 at 12 weeks < 10% change in HOMA-IR
CIRS, Water-Damaged Buildings, and Parkinson’s Disease
Staged assessment pathway. Credit: NDNR Studio 

 

Interventions, ordered by observed effect

Across the reviewed trials the ordering was consistent, and it is not the ordering most patients expect. Resistance training led; supplement protocols were adjunctive rather than primary.3

  1. Resistance training, 2×/week. Largest single effect on fasting insulin.
  2. Protein redistribution. 30 g at breakfast reduced afternoon glycemic excursions.
  3. Sleep consolidation. Treating the 3 a.m. waking improved morning cortisol and insulin together.
  4. Targeted nutrients. Inositol and magnesium as support, not substitution.
Practice note: Book the 12-week re-test at the same visit you start the protocol. Adherence and follow-through both drop sharply when the recheck is left to the patient to schedule.

 

Bringing it into the visit

The framework is designed to fit a standard follow-up rather than a dedicated metabolic consult: one added blood draw, one measurement, one exercise prescription, one scheduled recheck. Patients respond well to being told a window exists and that it is currently open.

Read Entire Article

         

        

Start the new Vibrations with a Medbed Franchise today!  

Protect your whole family with Quantum Orgo-Life® devices

  Advertising by Adpathway